After Glaxo's genital herpes vaccine flop, check out Agenus Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : After Glaxo's genital herpes vaccine flop, check out Agenus

GSK 46.86

-0.2%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: albertaft who wrote (20)	5/1/2015 4:59:41 AM
From: robert b furman	Read Replies (1) of 22

Possible billion pound drug - not too shabby. Alexandra Hauber, analyst at UBS, said its potential had been underestimated. She argued that peak annual sales of £1bn looked “very achievable” compared with the market’s consensus forecast for just £100m-£200m.Shingles, characterised by a painful skin rash, is caused by the reactivation of the latent varicella zoster virus, better known as chickenpox, often decades after the initial infection. The GSK study of 37,000 people, published on Tuesday in the New England Journal of Medicine, showed that HZ/su maintained its effectiveness across all age groups over 50. This promises to set it apart from the only existing shingles vaccine, made by Merck of the US, which has peak efficacy of 70 per cent among people aged 50-59, declining to 38 per cent among the over 70s.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next